IP
IPSEF.US Ipsen S.A.
- Market cap
- USD 9.33B
- P/E
- 19.4x
- P/B
- 2.29x
- ROE
- 34.2%
- Dividend yield
- 1.42%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is IPSEF.US undervalued?
Graham numberIPSEF.US trades 40.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ipsen S.A. fundamental analysis
No fundamental analysis for Ipsen S.A. yet.
Ipsen S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ipsen S.A.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, fema…
Full company profileIpsen S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ipsen S.A. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.67B | 2.01B | 2.35B | 2.69B | 2.69B | 3.00B | 3.16B | 3.31B | 3.57B | 3.67B | 8.75B |
| Gross Profit | 1.32B | 1.63B | 1.89B | 2.20B | 2.20B | 2.46B | 2.63B | 2.74B | 2.96B | 2.59B | 7.01B |
| Operating Income | 305M | 397M | 519M | -33.4M | 521M | 850M | 730M | 816M | 497M | 746M | 3.41B |
| EBITDA | 344M | 488M | 647M | 153M | 795M | 1.06B | 943M | 887M | 1.16B | 1.10B | 3.41B |
| Net Income | 226M | 272M | 390M | -50.7M | 548M | 647M | 649M | 644M | 346M | 444M | 1.61B |
| EPS | 2.73 | 3.28 | 4.68 | -0.61 | 6.57 | 7.76 | 7.81 | 7.73 | 4.14 | 5.32 | 19 |
| Balance Sheet | |||||||||||
| Total Assets | 2.42B | 3.07B | 3.38B | 4.31B | 4.32B | 5.01B | 5.61B | 6.32B | 6.44B | 6.94B | 7.45B |
| Total Liabilities | 1.06B | 1.54B | 1.53B | 2.55B | 2.20B | 2.25B | 2.27B | 2.50B | 2.26B | 2.60B | 2.75B |
| Shareholders' Equity | 1.36B | 1.53B | 1.84B | 1.75B | 2.12B | 2.75B | 3.34B | 3.83B | 4.18B | 4.33B | 4.70B |
| Cash & Short-term Investments | 432M | 258M | 350M | 413M | 691M | 857M | 1.20B | 528M | 679M | 1.52B | 1.97B |
| Total Debt | 304M | 362M | 336M | 853M | 871M | 693M | 3.80M | 306M | 427M | 867M | 962M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 318M | 423M | 571M | 628M | 771M | 909M | 971M | 866M | 916M | 1.14B | 2.72B |
| Capital Expenditure | 372M | 241M | 288M | 281M | 141M | 428M | 253M | 183M | 783M | 105M | 113M |
| Free Cash Flow | -54.5M | 182M | 283M | 347M | 631M | 482M | 719M | 683M | 133M | 1.03B | 2.60B |
| Ratios | |||||||||||
| ROE | 16.6% | 17.9% | 21.2% | -2.9% | 25.9% | 23.5% | 19.4% | 16.8% | 8.3% | 10.3% | 34.2% |
| ROA | 9.3% | 8.9% | 11.5% | -1.2% | 12.7% | 12.9% | 11.6% | 10.2% | 5.4% | 6.4% | 21.6% |
| Net Profit Margin | 13.5% | 13.5% | 16.6% | -1.9% | 20.4% | 21.6% | 20.5% | 19.5% | 9.7% | 12.1% | 18.4% |
| Debt to Equity | 0.22x | 0.24x | 0.18x | 0.49x | 0.41x | 0.25x | 0.00x | 0.08x | 0.10x | 0.20x | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ipsen S.A. dividends
- Dividend yield
- 1.42%
- Forward dividend
- 1.60 USD
- Payout ratio
- 26.1%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 116M | 1.39 | 26.1% |
| 2024 | EUR 99.6M | 1.19 | 28.8% |
| 2023 | EUR 99.6M | 1.19 | 15.5% |
| 2022 | EUR 99.3M | 1.19 | 15.3% |
| 2021 | EUR 82.9M | 0.99 | 12.8% |
| 2020 | EUR 83.2M | 1.00 | 15.2% |
| 2019 | EUR 83.2M | 1.00 | - |
| 2018 | EUR 83.0M | 1.00 | 21.3% |
| 2017 | EUR 70.2M | 0.85 | 25.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ipsen S.A.
- Insiders 57.64%
- Institutions 22.02%
- Public & others 20.34%
- Shares outstanding 82.4M
- Free float 30.0M
Ipsen S.A. company profile
- Company name
- Ipsen S.A.
- Ticker
- IPSEF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,535
- Fiscal year end
- December
- Address
- 70 rue Balard, Paris, France, 75015
- Phone
- 33 1 58 33 50 00
- Website
- ipsen.com
About Ipsen S.A.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.
Ipsen S.A. management
10- Mr. David LoewMD, CEO & Director · born 1967
- Mr. Aymeric Le ChatelierExecutive VP & CFO · born 1969
- Mr. Pierrick LefrancExecutive VP & Head of Technical Operations
- Mr. Henry Wheeler M.Sc.Global Vice President of Investor Relations · born 1984
- Ms. Caroline SitbonExecutive VP & General Counsel
- Ms. Sally BainHead of Global Media Relations
- Mr. Regis MulotExecutive VP & Chief Human Resources Officer · born 1966
- Mr. Philippe Lopes-Fernandes CBOExecutive VP & Chief Business Officer
- Ms. Mari ScheiffeleExecutive VP, Chief Product Officer & Head of GPPS
- Dr. Sandra Silvestri M.D., Ph.D.Executive VP & Chief Medical Officer · born 1974